Erasca, Inc. Net Income
Erasca, Inc. (ERAS) reported Net Income of -$44.08 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-11
- Erasca, Inc. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$44.08M.
- Erasca, Inc. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$183.44M.
- Erasca, Inc. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$29.09M.
- Erasca, Inc. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$30.61M.
- Erasca, Inc. net income (loss) attributable to parent for fiscal 2025 was -$124.55M.
- Erasca, Inc. net income (loss) attributable to parent for fiscal 2024 was -$161.65M.
- Erasca, Inc. net income (loss) attributable to parent for fiscal 2023 was -$125.04M.
- Erasca, Inc. net income (loss) attributable to parent for fiscal 2022 was -$242.81M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$44.08M 10-Q · filed 2026-08-11 | -$227.52M 10-Q · filed 2026-08-11 | -$256.61M derived: sum of 3 quarters · filed 2026-08-11 | -$287.22M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$183.44M 10-Q · filed 2026-08-11 | -$212.53M derived: sum of 2 quarters · filed 2026-08-11 | -$243.14M derived: sum of 3 quarters · filed 2026-08-11 | -$277.02M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$29.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$59.70M derived: sum of 2 quarters · filed 2026-03-12 | -$93.58M derived: sum of 3 quarters · filed 2026-08-11 | -$124.55M 10-K · filed 2026-03-12 |
| 2025-09-30 | -$30.61M 10-Q · filed 2025-11-12 | -$64.49M derived: sum of 2 quarters · filed 2026-08-11 | -$95.45M 10-Q · filed 2025-11-12 | -$127.69M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$33.88M 10-Q · filed 2026-08-11 | -$64.84M 10-Q · filed 2026-08-11 | -$97.07M derived: sum of 3 quarters · filed 2026-08-11 | -$128.27M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$30.97M 10-Q · filed 2026-08-11 | -$63.20M derived: sum of 2 quarters · filed 2026-08-11 | -$94.40M derived: sum of 3 quarters · filed 2026-08-11 | -$157.60M derived: sum of 4 quarters · filed 2026-08-11 |
| 2024-12-31 | -$32.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$63.43M derived: sum of 2 quarters · filed 2026-03-12 | -$126.63M derived: sum of 3 quarters · filed 2026-03-12 | -$161.65M 10-K · filed 2026-03-12 |
| 2024-09-30 | -$31.20M 10-Q · filed 2025-11-12 | -$94.40M derived: sum of 2 quarters · filed 2025-11-12 | -$129.42M 10-Q · filed 2025-11-12 | -$159.12M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$63.20M 10-Q · filed 2025-11-12 | -$98.22M 10-Q · filed 2025-08-12 | -$127.92M derived: sum of 3 quarters · filed 2025-11-12 | -$158.28M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-03-31 | -$35.02M 10-Q · filed 2025-11-12 | -$64.72M derived: sum of 2 quarters · filed 2025-11-12 | -$95.08M derived: sum of 3 quarters · filed 2025-11-12 | -$126.86M derived: sum of 4 quarters · filed 2025-11-12 |
| 2023-12-31 | -$29.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$60.06M derived: sum of 2 quarters · filed 2025-03-20 | -$91.84M derived: sum of 3 quarters · filed 2025-03-20 | -$125.04M 10-K · filed 2025-03-20 |
| 2023-09-30 | -$30.36M 10-Q · filed 2024-11-12 | -$62.14M derived: sum of 2 quarters · filed 2024-11-12 | -$95.34M 10-Q · filed 2024-11-12 | -$230.59M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$31.78M 10-Q · filed 2024-11-12 | -$64.98M 10-Q · filed 2024-08-12 | -$200.23M derived: sum of 3 quarters · filed 2024-11-12 | -$235.72M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-03-31 | -$33.20M 10-Q · filed 2024-11-12 | -$168.45M derived: sum of 2 quarters · filed 2024-11-12 | -$203.94M derived: sum of 3 quarters · filed 2024-11-12 | -$239.55M derived: sum of 4 quarters · filed 2024-11-12 |
| 2022-12-31 | -$135.25M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | -$170.74M derived: sum of 2 quarters · filed 2024-03-27 | -$206.35M derived: sum of 3 quarters · filed 2024-03-27 | -$242.81M 10-K · filed 2024-03-27 |
| 2022-09-30 | -$35.49M 10-Q · filed 2023-11-09 | -$71.10M derived: sum of 2 quarters · filed 2023-11-09 | -$107.56M 10-Q · filed 2023-11-09 | -$138.02M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$35.61M 10-Q · filed 2023-11-09 | -$72.07M 10-Q · filed 2023-08-10 | -$102.53M derived: sum of 3 quarters · filed 2023-11-09 | -$148.60M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-03-31 | -$36.46M 10-Q · filed 2023-11-09 | -$66.92M derived: sum of 2 quarters · filed 2023-11-09 | -$112.99M derived: sum of 3 quarters · filed 2023-11-09 | -$141.21M derived: sum of 4 quarters · filed 2023-11-09 |
| 2021-12-31 | -$30.46M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$76.53M derived: sum of 2 quarters · filed 2023-03-23 | -$104.75M derived: sum of 3 quarters · filed 2023-03-23 | -$122.76M 10-K · filed 2023-03-23 |
| 2021-09-30 | -$46.07M 10-Q · filed 2022-11-09 | -$74.28M derived: sum of 2 quarters · filed 2022-11-09 | -$92.30M 10-Q · filed 2022-11-09 | -$154.20M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$28.21M 10-Q · filed 2022-11-09 | -$46.23M 10-Q · filed 2022-08-11 | -$108.13M derived: sum of 3 quarters · filed 2022-11-09 | -$118.74M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-03-31 | -$18.02M 10-Q · filed 2022-11-09 | -$79.92M derived: sum of 2 quarters · filed 2022-11-09 | -$90.53M derived: sum of 3 quarters · filed 2022-11-09 | -$96.02M derived: sum of 4 quarters · filed 2022-11-09 |
| 2020-12-31 | -$61.90M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | -$72.51M derived: sum of 2 quarters · filed 2022-03-24 | -$78.00M derived: sum of 3 quarters · filed 2022-03-24 | -$101.66M 10-K · filed 2022-03-24 |
| 2020-09-30 | -$10.61M 10-Q · filed 2021-11-10 | -$16.10M derived: sum of 2 quarters · filed 2021-11-10 | -$39.76M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$5.49M 10-Q · filed 2021-11-10 | -$29.15M 10-Q · filed 2021-08-26 | ||
| 2020-03-31 | -$23.66M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |